Capstan Therapeutics Announces $175 Million
Oversubscribed Series B

San Diego – March 20, 2024 – Cooley advised Capstan Therapeutics, a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery using targeted lipid nanoparticles (tLNP), on the close of its $175 million oversubscribed Series B financing. Lawyers Ken Rollins, Edmond Lay and Heidi Wang led the Cooley team advising Capstan.

The financing was led by RA Capital Management, with participation from new investors Forbion, Johnson & Johnson Innovation – JJDC, Mubadala Capital, Perceptive Advisors and Sofinnova Investments, as well as existing investors Alexandria Venture Investments, Bristol Myers Squibb, Eli Lilly and Co., Leaps by Bayer, Novartis Venture Fund, OrbiMed, Pfizer Ventures, Polaris Partners, and Vida Ventures.

Capstan will use proceeds from the financing round to further develop its tLNP pipeline, as well as advance the company’s lead in vivo chimeric antigen receptor T cell candidate, CPTX2309, to early clinical proof of concept in autoimmune disorders.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has more than 1,300 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of nearly 3,000.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.